IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF CALIFORNIA
July 14, 2008
THERASENSE, INC., PLAINTIFF,
BECTON, DICKINSON AND COMPANY, DEFENDANT.
The opinion of the court was delivered by: William A Lsup United States District Judge
ORDER DENYING AND CONSOLIDATED CASES. DEFENDANT'S MOTION TO DISMISS
Abbott Laboratories filed this action alleging infringement of U.S. Patent No. 5,628,890 in March 2005. Over three years have since passed. Now, one week before the trial on the '890 is set to begin, BD/Nova moves to dismiss Abbott's infringement claim on the newly discovered allegation that Abbott is not the owner of the '890 patent and therefore has no standing to sue for infringement. Despite being in litigation for three years, BD/Nova contends that it only discovered the ground for its motion within the past month. For the reasons set forth below, BD/Nova's motion is DENIED.
The '890 patent was assigned to Medisense, Inc., in 1996. Abbott was Medisense's sole owner and shareholder. Medisense dissolved on December 31, 1998. BD/Nova's motion is entirely premised on the fact that there is no written document evidencing a transfer of ownership rights in the '890 patent from Medisense to Abbott. But BD/Nova has previously stipulated that Abbott is the owner of the '890 patent. Specifically, in the joint pretrial order BD/Nova stipulated that "Abbott Laboratories owns the '890 Patent" (Parties' Joint Proposed Pretrial Order at 16). A joint pretrial order lays out those issues that are disputed for trial and stipulations therein are binding at trial. See Malhiot v. S. Cal. Retial Clerks Union, 735 F.2d 1133, 1137 (9th Cir. 1984). In addition, while a party may not stipulate to federal subject- matter jurisdiction, it can stipulate to facts from which jurisdiction can be inferred. See United States v. Mathews, 833 F.2d 161, 164 (9th Cir. 1987). Ordinarily when a company dissolves, its assets are distributed to its shareholders or to its owner. Here, Abbott was the sole shareholder of Medisense at the time of its dissolution. It appears therefore that Abbott would have become the de facto owner of the '890 patent after Medisense's dissolution. BD/Nova contends otherwise. The contention must be rejected.
Under BD/Nova's logic, nobody owns the '890 patent and it is instead simply floating in the ether. Fortunately, we do not have to get into metaphysics for BD/Nova has already stipulated that Abbott is the owner of the '890 patent - a stipulation for which BD/Nova has shown no cause to withdraw from. The only argument BD/Nova makes is that its stipulation was written in the present tense - i.e., "Abbott Laboratories owns the '890 Patent" - and the relevant inquiry for standing purposes is whether ownership was established at the time the complaint was filed. See Gaia Tech., Inc. v. Reconversion Tech., Inc., 93 F.3d 774, 777 (Fed. Cir. 1996). BD/Nova's pedantic argument is without merit. BD/Nova has not explained how Abbott could be the owner of the '890 patent today and not the owner of the patent in March 2005. They have also not given any significant justification for its failure to raise this issue earlier (even in the joint pretrial order) rather than on the eve of trial. Given the immediacy of the impending trial, the prejudice to Abbott is clear. Prejudice to the Court's calender is also manifest. The Court informed the parties two months ago that it would reserve the time to try this case now and that it would otherwise have to wait until sometime in 2009. For these reasons, BD/Nova's motion must be DENIED.
IT IS SO ORDERED.
© 1992-2008 VersusLaw Inc.